Menu
With thought-leaders from finance, healthcare and psychedelics, Psych Capital is the UK’s and Europe’s primary incubator in psychedelic science and healthcare.
Co-Founder & CIO
William has been an active investor in psychedelics healthcare since 2020, being a lead investor in Awakn Life Sciences at an early stage. He brings an extensive network of high net worth and institutional investors to the table.
William has been specifically focused on the healthcare sector for a number of years now, including co-founding European cannabis investment firm, Goodplant Ventures in 2021.
Co-Founder & Executive director
Co-founder of Psych Capital Plc.He founded PSYCH in early 2019 to provide data and intelligence on the emerging psychedelics industry. He is also CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry’s best-known B2B companies and brands including Prohibition Partners, Business of Cannabis, Cannabis Europa and Atalis.
Stephen’s background is in technology, digital media and corporate finance, including roles with Sony Pictures, Unilever and Diageo.
Non-executive Director, Co-Founder, Shortwave Pharma
Roy has over 15 years of entrepreneurial, corporate finance and strategy experience working in Israel, Europe and LATAM markets. Leading strategy and M&A at IMC (NASDAQ: IMCC, CSE: IMCC) with total activity of over US$180m. Formerly director of Israeli operations at MSW Capital, a Rio-based Brazilian M&A and advisory boutique firm leading business development and investment transactions between Israel and Brazil. Roy has served as senior consultant at Israel KPMG corporate finance. Mr Kait is a pilot (res.) in the Israeli air force.
CEO and Board Member, Co-Founder, Shortwave Pharma
Rivki is a Certified Public Accountant (Isr.) with a broad range of finance, strategy and business development expertise, helping to scale IP-driven start-ups in the field of life sciences. Rivki’s international experience in Asia and North America includes raising of over USD 30M for life sciences and biotech companies in the fields of diagnostics, microbiome and aesthetics, and leading go-public campaigns (NASDAQ: IMCC, CSE:IMCC). Rivki served as member of the board at several life-sciences companies and academic institutions, and as consultant to the Israeli government, accelerator programmes and investment funds.
Co-Founder & CIO
William has been an active investor in psychedelics healthcare since 2020, being a lead investor in Awakn Life Sciences at an early stage. He brings an extensive network of high net worth and institutional investors to the table.
William has been specifically focused on the healthcare sector for a number of years now, including co-founding European cannabis investment firm, Goodplant Ventures in 2021.
Co-Founder & Executive director
Co-founder of Psych Capital Plc.He founded PSYCH in early 2019 to provide data and intelligence on the emerging psychedelics industry. He is also CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry’s best-known B2B companies and brands including Prohibition Partners, Business of Cannabis, Cannabis Europa and Atalis.
Stephen’s background is in technology, digital media and corporate finance, including roles with Sony Pictures, Unilever and Diageo.
Managing Director
10 + years in leadership roles in tech startups across London, SF and Stockholm within business development and strategic communications. First employee at iZettle in the UK (acquired by PayPal for $2.2B).
With postgraduate studies in Psychology & Neuroscience, and working with coaching/ consulting start-up founders in the AI space, Christina’s passion lies in the intersection of mental health and scaling hyper-growth companies.
Associate
Worked on the launch of multiple start-ups including DoinGud (NFT creator’s platform), Tutorbloc (ed-tech marketplace she co-founded and secured Innovate UK funding), and the psychedelic venture studio, Beckley Waves.
Beriwan centres upon research and investments at Psych Capital, bringing her passion for driving entrepreneurial impact across the industry.
Advisor
A Chartered Psychologist and Head of Research at Drug Science (the leading independent scientific body on drugs in the UK).
Leads the research for the Drug Science Medical Cannabis and Psychedelics Working Group.,including the improvement of patient access, with expertise across science and policy making, risk perception, risk management and risk communication.
Honorary Fellowships at Imperial College London and King’s College London.
Advisor
Investment banker with 25 years experience across the US and UK.
Managing Director at Stifel in New York and previously a board member of Stifel Nicolaus Europe Ltd and Head of the European fixed income business.
Previous director or vice president roles at Knight Capital Group, UBS, Barclays Capital, RBC Capital Markets and Scotiabank.
© 2022 Psych Capital Plc.
All Rights Reserved.
